Navigation Links
FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
Date:7/8/2008

First Organ-specific MRI Contrast Agent Approved in the United States in

More Than a Decade

WAYNE, N.J., July 8 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc., a leader in diagnostic imaging, announced today that the U.S. Food and Drug Administration (FDA) has approved EOVIST(R) (Gadoxetate Disodium) Injection, a gadolinium-based contrast agent, for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease. The approval makes EOVIST the first organ-specific MRI contrast agent approved in the United States in more than a decade.

"The approval of EOVIST in the United States marks a significant achievement in advancing the accurate diagnosis of liver disease," said Douglas Stefanelli, Vice President and General Manager, Diagnostic Imaging, Bayer HealthCare Pharmaceuticals. "This milestone demonstrates Bayer HealthCare Pharmaceuticals' commitment to providing innovative imaging products that can help improve the lives of patients."

EOVIST is a paramagnetic MRI contrast agent that combines features of both an extracellular contrast agent and a hepatocyte-specific agent. EOVIST is administered via an intravenous, bolus injection and has a dual route of excretion with approximately 50 percent eliminated through the liver and 50 percent eliminated through the kidney. Detection and characterization of malignant and benign focal liver lesions with EOVIST may help enhance diagnostic accuracy and increase diagnostic confidence.

"EOVIST-enhanced images can provide more comprehensive information about focal liver lesions in a single, short imaging session than was previously available," said Jeffrey Brown, MD, Professor of Radiology, Washington University School of Medicine, St. Louis. "With the availability of EOVIST, our ability to evaluate patients with benign and malignant focal hepatic lesions will
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
2. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
3. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
4. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
5. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
6. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
7. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
8. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
9. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
10. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
11. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... March 3, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... scientific journal, Expert Opinion on Biological Therapy , ... Zhenggang Zhang , at the Henry Ford Hospital ... Thymosin beta 4 (TB4) has the capacity to promote ... or more post-injury, leading to neurological recovery in each ...
(Date:3/3/2015)... 2015 Becht Engineering Co., Inc., ... has acquired The CECON Group, Inc., located in ... not announced. , Becht Engineering (http://www.becht.com ) ... including oil and gas production, refining, petrochemical, chemical, ... power sectors. The company has twelve offices in ...
(Date:3/3/2015)... 03, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Gene Therapy - ... , Gene therapy technologies are ... and cell therapy with genetically modified vectors. Gene ... and various routes of administration as well as ...
(Date:3/3/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... announced it has initiated commissioning activities for its 30,000 ... Sarnia, Ontario , Canada.  Commissioning ... with the facility being in commercial operation in Q3 ... two months and it is carrying out commissioning and ...
Breaking Biology Technology:Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3BioAmber Begins Commissioning of Sarnia Commercial Plant 2BioAmber Begins Commissioning of Sarnia Commercial Plant 3
... you, it was in the middle of a week's trip to ... a new trade office in that country. The initial part of ... ancient capitol of Agra (home to the Taj Mahal among other ... part of the trip. I promised to share with you both ...
... Whenever the title executive vice president is part of a ... management. So it is with Judy Lemke, who was lured ... career that she thought was winding down. , ,Lemke, executive ... global transportation, logistics, and intermodal services, was recruited to be ...
... have provided people with many items such as ... digital audio capabilities. Technology is evolving so quickly ... 10 years ago are now taken for granted. ... and understand how technology may evolve when entering ...
Cached Biology Technology:A Midwest passage to India, Part II 2A Midwest passage to India, Part II 3A Midwest passage to India, Part II 4A Midwest passage to India, Part II 5A Midwest passage to India, Part II 6A Midwest passage to India, Part II 7A Midwest passage to India, Part II 8CIO Leadership Series: Judy Lemke, Schneider National 2CIO Leadership Series: Judy Lemke, Schneider National 3CIO Leadership Series: Judy Lemke, Schneider National 4CIO Leadership Series: Judy Lemke, Schneider National 5Making deals with evolving technologies in mind 2Making deals with evolving technologies in mind 3Making deals with evolving technologies in mind 4Making deals with evolving technologies in mind 5
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
(Date:2/5/2015)... 28, 2015 Research and Markets ... the "Global Biometrics Market (2014-2020): Market Forecast ... report to their offering. , ... is anticipated to overtake ... increasing government spending towards IT security, government biometric ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... scientists are working together to meet the challenges of climate ... Biology on 28th June will demonstrate innovative techniques and insights ... crop yields and diminishing fish stocks. , In seven ... world,s four most important crops has fallen short of demand, ...
... advance toward treating disease with minute capsules containing not ... for making the drug. In an article in ACS, ... and nano-sized capsules that contain the genetically coded instructions, ... synthesis that can be switched on with an external ...
... international team led by human genetic researchers at the ... identified the latest gene associated with typical late-onset Lewy ... Canadian Mennonite family of Dutch-German-Russian ancestry. Twelve ... participated in the study had previously been diagnosed with ...
Cached Biology News:Parkinson's disease gene identified with help of Mennonite family: UBC-VCH research 2Parkinson's disease gene identified with help of Mennonite family: UBC-VCH research 3
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Use the DUALmembrane kit 3 to carry out DUALmembrane interaction analysis and cDNA library screening to characterize interactions between integral membrane proteins and to identify novel interaction ...
... effectively seals labware. Waterproof, moisture-proof film ... materials. Can be folded repeatedly and ... Stretched lengthwise at 21C (70F), wrapping ... tension is removed, film only partially ...
Biology Products: